Cargando…
The pioneer factor PBX1 is a novel driver of metastatic progression in ERα-positive breast cancer
Over 30% of ERα breast cancer patients develop relapses and progress to metastatic disease despite treatment with endocrine therapies. The pioneer factor PBX1 translates epigenetic cues and mediates estrogen induced ERα binding. Here we demonstrate that PBX1 plays a central role in regulating the ER...
Autores principales: | Magnani, Luca, Patten, Darren K., Nguyen, Van T.M., Hong, Sung-Pil, Steel, Jennifer H., Patel, Naina, Lombardo, Ylenia, Faronato, Monica, Gomes, Ana R., Woodley, Laura, Page, Karen, Guttery, David, Primrose, Lindsay, Garcia, Daniel Fernandez, Shaw, Jacqui, Viola, Patrizia, Green, Andrew, Nolan, Christopher, Ellis, Ian O., Rakha, Emad A., Shousha, Sami, Lam, Eric W.-F., Győrffy, Balázs, Lupien, Mathieu, Coombes, R. Charles |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4673133/ https://www.ncbi.nlm.nih.gov/pubmed/26215677 |
Ejemplares similares
-
DMXL2 drives epithelial to mesenchymal transition in hormonal therapy resistant breast cancer through notch hyper-activation
por: Faronato, Monica, et al.
Publicado: (2015) -
PBX1 Genomic Pioneer Function Drives ERα Signaling Underlying Progression in Breast Cancer
por: Magnani, Luca, et al.
Publicado: (2011) -
Differential epigenetic reprogramming in response to specific endocrine therapies promotes cholesterol biosynthesis and cellular invasion
por: Nguyen, Van T. M., et al.
Publicado: (2015) -
Author Correction: Differential epigenetic reprogramming in response to specific endocrine therapies promotes cholesterol biosynthesis and cellular invasion
por: Nguyen, Van T. M., et al.
Publicado: (2019) -
Nicastrin and Notch4 drive endocrine therapy resistance and epithelial to mesenchymal transition in MCF7 breast cancer cells
por: Lombardo, Ylenia, et al.
Publicado: (2014)